HTGM - HTGM STOCK NEWS

HTG Molecular Diagnostics reported a 45% revenue increase from Q1 to Q2 2021, achieving $2.1 million in total revenue, compared to $2.0 million in Q2 2020. The company launched the HTG Transcriptome Panel, with initial commercial orders contributing to growth. Additionally, HTG formed a new drug discovery unit, HTG Therapeutics, aimed at enhancing drug candidate development. Despite a net loss of $4.1 million, this is an improvement from $5.0 million in Q2 2020. Cash and equivalents stand at $29.8 million.

HTG Molecular Diagnostics announced the commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using HTG EdgeSeq technology. The product is now available in the U.S. and Europe after successful testing and a third white paper release. This panel aims to aid profiling in various cancers and is a cornerstone for HTG's new therapeutics unit. Enhanced features include low sample input and high sensitivity. The company anticipates strong market interest based on early collaborations.

HTG Molecular Diagnostics (HTGM) announced it will release its financial results for Q2 2021 on August 12, 2021, after market close. A conference call with investors is scheduled for 4:30 PM ET on the same day, aimed at discussing the financial outcomes and corporate updates. HTG is dedicated to advancing precision medicine through its proprietary HTG EdgeSeq technology, which enables complex molecular profiling from limited samples.

HTG Molecular Diagnostics (HTGM) announced the grant of stock options totaling 30,000 shares to two new employees, with exercise prices of $5.85 and $5.42, reflecting HTG’s closing prices on July 13 and July 22, 2021. These options vest over four years and are part of HTG’s 2021 Inducement Plan, aimed at attracting talent to further advance the company's mission in precision medicine. The options are subject to the employees' continuous service with the company and have a 10-year term.

HTG Molecular Diagnostics has established a new unit, HTG Therapeutics, aimed at advancing drug discovery by utilizing its HTG Transcriptome Panel. This unit will leverage the capabilities of the HTG EdgeSeq platform to expedite the development of drug candidates by profiling RNA modifications. The HTG Transcriptome Panel is set to launch commercially in August 2021 and is anticipated to enhance data generation for various disease states. The company's focus includes early partnerships with biopharma firms to improve drug development processes and address critical health areas like oncology.

HTG Molecular Diagnostics, Inc. (HTGM) announced the receipt of its first commercial orders for the HTG Transcriptome Panel and has signed Early Adopter Program (EAP) agreements in Europe and the US. The panel, set for a Q3 2021 launch, aims to measure around 20,000 mRNA targets using HTG EdgeSeq technology. The company has engaged prestigious cancer centers, including Fundación Instituto Valenciano de Oncologia and Tyrolpath Obrist Brunhuber GmbH, indicating strong interest and enthusiasm for the panel.

HTG Molecular Diagnostics (Nasdaq: HTGM) announced the completion of product design lock for its anticipated HTG Transcriptome Panel, expected to launch in Q3 2021. This panel will measure around 20,000 mRNA targets and is part of the Early Adopter Program (EAP) involving collaborations with notable institutions like the University of Texas MD Anderson Cancer Center and Duke University Medical Center. The demand for the EAP has exceeded expectations, with plans for a global commercial launch continuing as scheduled.

HTG Molecular Diagnostics (HTGM) announces that its HTG EdgeSeq technology is featured in multiple posters at the virtual American Society of Clinical Oncology (ASCO) conference from June 4-8, 2021. Notable abstracts include studies on durvalumab in triple-negative breast cancer and innovative approaches for determining recurrence risk in early-stage breast cancer. HTG's technology aids in molecular profiling, emphasizing precision medicine. The company expresses optimism regarding future customer growth and market penetration, showcasing its commitment to advancing precision medicine.

HTG Molecular Diagnostics reported financial results for Q1 2021, showing total revenue of $1.4 million, down from $2.2 million in Q1 2020, attributed to COVID-19 impacts. The net loss decreased to $4.6 million, with a net loss per share of $(0.80). The company is progressing on its transcriptome panel using HTG EdgeSeq technology, with anticipated commercialization by Q3 2021. Cash and equivalents stood at $30.8 million. The ongoing Early Adopter Program has seen increased participation, refining study details with over 25 collaborators from academia and pharma.